Stockreport

Loss-Making Candel Therapeutics, Inc. (NASDAQ:CADL) Expected To Breakeven In The Medium-Term [Yahoo! Finance]

Candel Therapeutics, Inc.  (CADL) 
PDF Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients. With the latest financial year loss of US$55m an [Read more]